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Background: Viral hepatitis exists throughout the world and is a major global public health problem affecting
millions of people. Hepatitis B (HBV) and hepatitis C (HCV) virus are the commonest causes of inflammation of the
liver leading to chronic liver disease, cirrhosis, hepatocellular carcinoma and even fulminant hepatitis. The objective
of this retrospective study was to determine the prevalence of infections with HBV and HCV among patients with
chronic hepatitis who visited Bereka Medical Center, southeast Ethiopia.
Methods: Institution based retrospective study design was employed. HBV and HCV test records of all patients with
chronic hepatitis who visited Bereka Medical Center from Nov. 2012 to Nov. 2013. A total of 578 (358 for HBV and
220 for HCV) patients with chronic hepatitis screened and the results of all patients were included. All sera were
screened using commercially available rapid test kits. Test results were shown in percent and prevalence rates.
Results: The overall prevalence of HBV and HCV among chronic hepatitis patients were 22.3% and 3.6% respectively.
Prevalence of HBV and HCV among males from the total HBV and HCV screened was 52/358 (14.5%) and 6/220 (2.7%)
respectively. 64/80 (80%) of HBV sero-positives were found in between 16 to 45 years of age. Of those 64 HBV sero-
positive patients, 42/64 (65.6%) were found 16–30 age interval. Furthermore, of those HCV infected, 6/8 (75%) of them
fall under 16–30 years of age. 6/8 (75%) of HCV infected patients were males.
Conclusion: The present study has shown that HBV was highly prevalent among patients who visited the clinic. Males
were more susceptible than female patients. 3.6% HCV prevalence was also high. Mass immunization of HBV is
recommended to halt HBV infection.
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Viral hepatitis exists throughout the world and is a
major global public health problem. It is an inflamma-
tion of the liver leading to chronic liver disease, cirrhosis,
hepatocellular carcinoma and even fulminant hepatitis.
The most common causes are hepatitis B virus (HBV) and
hepatitis C virus (HCV) [1]. HCV is an enveloped single-
stranded positive sense RNA virus belonging to the genus* Correspondence: salbertnick@yahoo.com
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a partially double-stranded circular DNA belonging to the
family Hepadnaviridae in the genus Orthohepadnavirus.
HBV causes acute hepatitis of varying severity and persists
in 95% of children and 10% of adult patients [3]. In
Ethiopia, 12% of hospital admissions and 31% of mortal-
ities in medical ward are due to liver disease [4].
Both virus share common mechanism of transmission
(parental, sexual and mother to child) and HBV is 50 to
100 times more infectious than HIV [4,5]. It is estimated
that more than 2 billion people in the world have been
infected with HBV. Of these, more than 360 million are
chronically infected and they are at risk of serious illnessd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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[6]. The burden of HBV infection is highest in the devel-
oping world particularly in Asia and sub-Saharan Africa.
WHO estimated that the prevalence of HBV infection in
Africa is on average more than 10%. However, a study
conducted in Addis Ababa showed that the mean preva-
lence of HBsAg was 6.1% [7,8].
WHO estimated also that approximately 170 million
people are infected with HCV and about 130 million are
carriers and three to four million persons are newly in-
fected each year and more than 350,000 people esti-
mated to die from HCV-related liver diseases each year
worldwide. HCV infection in the world varies from 0.3
to 13% or more with the highest prevalence recorded in
Central Africa and South-Eastern Asia. However, a study
in Addis Ababa showed that 0.9% prevalence among popu-
lation and 1.3% among adults over 15 years of age [8,9].
In the present study area, the information on the
prevalence of those hepatovirus is not known. Thus, the
aim of this study is to determine the prevalence of HBV
and HCV among patients with chronic hepatitis who vis-
ited Bereka Medical Center, southeast, Ethiopia.
Methods
The study was conducted at Bereka Medical Center in
Bale Robe town, bale zone, Oromia regional state, south-
east, Ethiopia. Institution based retrospective study de-
sign was used and the screening data’s of HBV and HCV
of all patients with chronic hepatitis who visited the
clinic from Nov 2012 to Nov 2013 were considered for
the study. All patients with chronic hepatitis were
screened for possible hepatoviral infection. During the
study period, a total of 578 (358 for HBV and 220 for
HCV) patients were screened for HBsAg and anti- HCV
and the results all patients were included for the present
study.
Standard procedures were followed during blood sam-
ple collection. All sera were screened for HBsAg and
antibodies to HCV using commercially available screen-
ing rapid test kits according to the manufacturer's in-
struction (Qualpro Diagnostics, 88/89, phase IIC, Verma
Industrial Estate, Verna, Goa-403 722, India). The testTable 1 Distribution of chronic hepatitis B and C virus infecte
Bereka Medical Center, Southeast, Ethiopia (Nov 2012-Nov 20
Hepatovirus
Age group
< 15 16-30 31-
Male Female Male Female Male
HBV 4 - 24 18 16
Total 4 42
HCV - - 4 2 2
Total - 6
HBV - Hepatitis B virus; HCV – Hepatitis C virus.kit has a sensitivity of 100% and specificity of 99.7%.
Positive serum samples were assayed in duplicate to in-
crease the quality of the procedure.
Data entry and analysis was done using SPSS version
16 computer software. Data was summarized and pre-
sented in a descriptive measure such as a table, figures,
mean and percent.
The study was approved by the Research Ethics and
Review Committee of Madawalabu University. Records
of patients were manipulated only by researchers. HBV
and HCV-positive cases were contacted with nurses and
doctors for further management.
All patients involved in this report were provided a
written informed consent prior to data collection. Fur-
thermore, written informed consent was obtained from
the each patient for publication.
Result
A total of 578 (358 for HBV and 220 for HCV) patients
with chronic hepatitis were included for the purpose of
this retrospective study. The age of patients’ ranges from
twelfth to fifty two years and the mean age of the study
population were 34 years. Male to female ratio of the pa-
tients were 1.2:1 and 1.3:1 for HBV and HCV respectively.
Blood screening results showed that hepatoviral infec-
tions were common among patients having chronic
hepatitis who visited the clinic. In the present retro-
spective study, the overall prevalence of HBV and HCV
was 22.3% and 3.6% respectively among patients with
chronic hepatitis. Prevalence of HBV among males from
the total HBV screened was 52/358 (14.5%) and from
the total screened males was 52/198 (26.3%). 64/80
(80%) of HBV positives were found in between 16 to
45 years. Of those 64 HBV positive patients, 42/64
(65.6%) were found 16–30 age group and further 40/64
(62.5%) of them are males. Four patients infected with
HBV were children under the age of 15 years and there
were no infected children in this age group (Table 1).
Whereas the prevalence of HCV from the total HCV
screened and from the total screened males was 6/220
(2.7%) and 6/124 (4.8%) respectively. All of the infected
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under 16–30 years of age. 6/8 (75%) of patients were
males and none of patients under the age of 15 and > 45
were infected (Table 1). In areas where viral hepatitis is
highly prevalent, co-infection of hepatoviral pathogens is
common. HBV/HCV co-infection in the present study
was 3/62 (4.8%).
Discussion
Hepatitis B and C virus infections are one of the major
diseases of mankind and are a serious global public
health problem [1,9]. The present retrospective study
aimed at determining the prevalence’s of HBV and HCV
infections among patients with chronic hepatitis who vis-
ited Bereka Medical Center, from Nov 2012- Nov 2013.
In this study, the overall prevalence of HBV was 80
(22.3%) which was much higher than the previous stud-
ies conducted in different parts of Ethiopia; Bulle Hora
(0.9%) by Amaha et al., Shashemene (5.7%) by Asfaw
et al. and Gondar (1.0%) by Belay et al. [6,8] and other
countries; Angola (15.1%) by Fatima et al. [7]. In
contrast, the present study is very much lower when
compared with the study conducted in Kumasi, Ghana
(71.0%) by Jean-Pierre Allain et al. [10]. These differ-
ences in prevalence could be due to the place and living
standard of study subjects or due to a reflection of the
local endemicity and life style of the study area.
Unavailability of HBsAg mass immunization schemes
makes HBV infection a major public health problem glo-
bally and especially in sub-Saharan countries [11]. The
same is true for Ethiopia and study area which accounts
the high prevalence because of unsafe sexual intercourse,
lack of specific confirmatory test in blood bank and
sharing sharp materials in unaware community.
Hepatitis C virus prevalence (3.6%) in the present
study was high when compared with other studies in
Ethiopia. The prevalence of HCV is quite different among
different communities. For instance, Taye and Lakew
study among HIV patients in Addis Ababa showed a
prevalence of 6.5% [9]. Another study at Gondar town
health institutions northwest Ethiopia indicated 0.0%
among medical waste handlers [8] which was very low
compared with the present study.
In western countries, HCV is highly prevalent primar-
ily because of injection drug use. Whereas in Ethiopia
the habit of injection drug use is very low thus might be
responsible for low HCV prevalence of HCV in the
community [9].
Furthermore, a study by Taye and Lakew and others
clearly indicated HCV infection increases with age in-
crease [9]; however, in this study its prevalence was high
in the age group 16–30 years and as age increases the
infection rate decreases (Table 1). The reason may be re-
lated to the effect of hormone and immunity.Conclusion
The present study has shown that HBV was highly
prevalent among patients with chronic hepatitis whom
visited the clinic during Nov. 2012-Nov. 2013. Further-
more, 3.6% HCV prevalence in the present study was
also high when compared with other community based
studies in Ethiopia. The absence of confirmatory tests
for both HBV and HCV might further compromise the
sensitivity and specificity of the results.
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